Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Cancers
•
Gastrointestinal Cancers
How do you manage urgency and frequency of bowel movements secondary to radiation proctitis?
Answer from: Radiation Oncologist at Community Practice
In the acute setting we try anusol HC suppository to decrease tenesmus like symptoms
Comments
Radiation Oncologist at Fox Chase Cancer Center
I agree. There’s not a lot of data here, but we ...
609
Sign in or Register to read more
3402
Related Questions
Would you offer inguinal nodal RT to a patient with anal SCC (pT1N1a, + inguinal node) following APR in the setting of prior prostate + pelvic nodal radiation?
How do you approach repeat SBRT in the abdomen, specifically when considering constraints for bowel and mesenteric vessels?
Would you ever start adjuvant pelvic radiation with a drain in place?
How do you sequence hypofractionated radiation and systemic therapy for patients with unresectable cholangiocarcinoma?
For a patient with IIIC1 (micromets), MSI-high, Grade 2 endometrial adenocarcinoma who has undergone full surgical staging, do you recommend adding immunotherapy to adjuvant chemotherapy + radiation?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
What dose and fields would you use for basosquamous carcinoma/basal cell carcinoma of the vulva s/p WLE but not fully excised due to adhesion to the rectum, with no further surgery offered?
Do you consider ablative radiation therapy for oligometastatic colon cancer with 5 pulmonary lesions responding to chemotherapy?
Do you use different dose constraints for large bowel vs. small bowel?
How would you treat an isolated recurrence in the pelvic muscle after prior definitive chemoradiation with brachytherapy boost for vaginal adenocarcinoma?
I agree. There’s not a lot of data here, but we ...